Cargando…

A randomized, placebo‐controlled clinical trial of hydrogen/oxygen inhalation for non‐alcoholic fatty liver disease

Non‐alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide with increasing incidence consistent with obesity, type 2 diabetes and cardiovascular diseases. No approved medication was currently available for NAFLD treatment. Molecular hydrogen (H(2)), an anti‐oxidativ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tao, Geru, Zhang, Guangjie, Chen, Wei, Yang, Chao, Xue, Yazhuo, Song, Guohua, Qin, Shucun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279585/ https://www.ncbi.nlm.nih.gov/pubmed/35734974 http://dx.doi.org/10.1111/jcmm.17456

Ejemplares similares

The effect of a low dose hydrogen-oxygen mixture inhalation in midlife/older adults with hypertension: A randomized, placebo-controlled trial
por: Liu, Boyan, et al.
Publicado: (2022)

Hydrogen inhalation alleviates nonalcoholic fatty liver disease in metabolic syndrome rats
por: Liu, Boyan, et al.
Publicado: (2020)

A strategy of local hydrogen capture and catalytic hydrogenation for enhanced therapy of chronic liver diseases
por: Tao, Geru, et al.
Publicado: (2023)

Molecular Hydrogen Inhibits Colorectal Cancer Growth via the AKT/SCD1 Signaling Pathway
por: Zhang, Xiangyan, et al.
Publicado: (2022)

Accurate in vivo real-time determination of the hydrogen concentration in different tissues of mice after hydrogen inhalation
por: Zhu, Wenjun, et al.
Publicado: (2022)

Acid‐Degradable Hydrogen‐Generating Metal‐Organic Framework for Overcoming Cancer Resistance/Metastasis and Off‐Target Side Effects
por: Yao, Xianxian, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease, to struggle with the strangle: Oxygen availability in fatty livers
por: Anavi, Sarit, et al.
Publicado: (2017)

Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial
por: Saadati, Saeede, et al.
Publicado: (2019)

Randomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson’s disease: a pilot study
por: Yoritaka, Asako, et al.
Publicado: (2021)

Hydrogen sulphide in liver glucose/lipid metabolism and non‐alcoholic fatty liver disease
por: Mateus, Inês, et al.
Publicado: (2021)

PCK1 activates oncogenic autophagy via down-regulation Serine phosphorylation of UBAP2L and antagonizes colorectal cancer growth
por: Zhang, Xiangyan, et al.
Publicado: (2023)

A narrative review of hydrogen-oxygen mixture for medical purpose and the inhaler thereof
por: Lin, Hsin-Yung, et al.
Publicado: (2020)

Cigarette smoke exposure impairs reverse cholesterol transport which can be minimized by treatment of hydrogen-saturated saline
por: Zong, Chuanlong, et al.
Publicado: (2015)

The effect of high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients. A randomized placebo controlled trial
por: Mohamed, Amal Ahmed, et al.
Publicado: (2023)

Inhalations of Oxygen
Publicado: (1885)

Inhalation of molecular hydrogen increases breath acetone excretion during submaximal exercise: a randomized, single-blinded, placebo-controlled study
por: Hori, Amane, et al.
Publicado: (2020)

Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Taheri, Hoda, et al.
Publicado: (2020)

The effect of combination therapy of allicin and fenofibrate on high fat diet-induced vascular endothelium dysfunction and liver damage in rats
por: Li, Weihong, et al.
Publicado: (2010)

Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease
por: Yu, Cheng-Wei, et al.
Publicado: (2023)

Effects of Quercetin Supplementation on Hematological Parameters in Non-Alcoholic Fatty Liver Disease: a Randomized, Double-Blind, Placebo-Controlled Pilot Study
por: Pasdar, Yahya, et al.
Publicado: (2020)

Are Ingested or Inhaled Microplastics Involved in Nonalcoholic Fatty Liver Disease?
por: Auguet, Teresa, et al.
Publicado: (2022)

Litchi-Derived Polyphenol Alleviates Liver Steatosis and Gut Dysbiosis in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Double-Blinded, Placebo-Controlled Study
por: Jinato, Thananya, et al.
Publicado: (2022)

Non-invasive methods to evaluate liver fibrosis in patients with non-alcoholic fatty liver disease
por: Wang, Jincheng, et al.
Publicado: (2022)

Randomised Double-Blind Placebo-Controlled Trial of Inulin with Metronidazole in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Chong, Clara Yieh Lin, et al.
Publicado: (2020)

Influence of oxygen concentration on the neuroprotective effect of hydrogen inhalation in a rat model of cardiac arrest
por: Wang, Jianjie, et al.
Publicado: (2022)

Impact of hydrogen gas inhalation during therapeutic hypothermia on cerebral hemodynamics and oxygenation in the asphyxiated piglet
por: Nakamura, Shinji, et al.
Publicado: (2023)

Inflammatory markers response to citrulline supplementation in patients with non-alcoholic fatty liver disease: a randomized, double blind, placebo-controlled, clinical trial
por: Darabi, Zahra, et al.
Publicado: (2019)

The effects of zinc supplementation on the metabolic factors in patients with non-alcoholic fatty liver disease: a randomized, double-blinded, placebo-controlled clinical trial
por: Rezaei, Seyed Mohammad Amin, et al.
Publicado: (2023)

Autophagy in non-alcoholic fatty liver disease and alcoholic liver disease()
por: Khambu, Bilon, et al.
Publicado: (2018)

Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver
por: Foroughi, Mehdi, et al.
Publicado: (2016)

Effectiveness and safety analysis of Danggui Shaoyao Powder for the treatment of non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled clinical trial
por: Huang, Qian, et al.
Publicado: (2023)

Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
por: Chehrehgosha, Haleh, et al.
Publicado: (2021)

A randomized, placebo‐controlled study to evaluate safety and pharmacokinetics of inhaled ribavirin
por: Couroux, Peter, et al.
Publicado: (2022)

Alcohol? Not for Non-alcoholic Fatty Liver Disease Patients
por: Cainelli, Francesca, et al.
Publicado: (2020)

Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials
por: Tang, Xue, et al.
Publicado: (2022)

Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease
por: Chao, Hsu-Wen, et al.
Publicado: (2019)

Abnormal metabolic processes involved in the pathogenesis of non-alcoholic fatty liver disease (Review)
por: Shao, Mingmei, et al.
Publicado: (2020)

Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial
por: Xue, Lanfeng, et al.
Publicado: (2022)

Zn-Fe primary battery-enabled controlled hydrogen release in stomach for improving insulin resistance in obesity-associated type 2 diabetes
por: Liu, Boyan, et al.
Publicado: (2023)

Molecular mechanism of alcoholic fatty liver
por: Rasineni, Karuna, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_u1o0k90j7vg5omqm1t9hsc1iuq